A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2013
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Acronyms FLUARIX-071
- Sponsors GlaxoSmithKline
- 10 Aug 2012 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.
- 04 Aug 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2012-000789-39).
- 19 Jul 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.